Arkolith/Insider Trading/OLMA/Form 4

Harmon Cyrus

DirectorOlema Pharmaceuticals, Inc. (OLMA) · full profile →Form 4 · filed Jan 21, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$269K
Net Open-Market Flow
-$269K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 20, 2026Sell(S)10K$26.88$269K728K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001831410-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML